Galena Biopharma (GALE) Misses Q2 EPS by 8c

Galena Biopharma (NASDAQ: GALE) reported Q2 EPS of ($0.17), $0.08 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $2.3 million versus the consensus estimate of $2.99 million.

For earnings history and earnings-related data on Galena Biopharma (GALE) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Integra LifeSciences cuts 2026 outlook after Cincinnati flood
• LTC Properties (LTC) PT Raised to $52 at RBC Capital